

1 Causes of false-negative rapid diagnostic tests for symptomatic malaria in the DRC

2
3 **Authors:** Jonathan B. Parr,^{1*#} Eddy Kieto,^{2*} Fernandine Phanzu,² Paul Mansiangi,³
4 Kashamuka Mwandagalirwa,³ Nono Mvuama,³ Ange Landela,⁴ Joseph Atibu,³ Solange
5 Umesumbu Efundu,⁵ Jean W. Olenga,² Kyaw Lay Thwai,¹ Camille E. Morgan,⁶ Madeline
6 Denton,¹ Alison Poffley,⁶ Jonathan J. Juliano,^{1,6} Pomie Mungala,² Joris L. Likwela,² Eric M.
7 Sompwe,⁵ Antoinette K. Tshefu,³ Adrien N'Siala,² Albert Kalonji²

8
9 * Co-first authors

10 **Affiliations:**

- 11 1. Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel
12 Hill, NC 27599, USA.
- 13 2. SANRU Asbl (Sante Rurale/Global Fund), Kinshasa, Democratic Republic of the Congo.
- 14 3. University of Kinshasa School of Public Health, Kinshasa, Democratic Republic of Congo.
- 15 4. Institut National pour La Recherche Biomedicale, Kinshasa, Democratic Republic of the
16 Congo.
- 17 5. Programme National de la Lutte contre le Paludisme, Kinshasa, Democratic Republic of
18 Congo.
- 19 6. Department of Epidemiology, Gillings School of Global Public Health, University of North
20 Carolina, Chapel Hill, NC 27599, USA.

21
22
23
24
25
26
27
28 **Running head:** Causes of false-negative malaria RDTs in the DRC

29 **Key words:** rapid diagnostic tests, histidine-rich protein 2, pfrhp3, hrp2, hrp3, RDT,
30 deletion, malaria, *Plasmodium falciparum*, *Plasmodium ovale*, *Plasmodium malariae*,
31 *Plasmodium vivax*, Congo

32 **Abstract word count:** 197

33 **Word count:** 3482

34
35
36 **# Corresponding author:** Jonathan B. Parr, MD, MPH, Division of Infectious Diseases,
37 University of North Carolina, 130 Mason Farm Rd., Chapel Hill, NC 27599; phone 1-919-
38 445-1132, email jonathan_parr@med.unc.edu

40 **ABSTRACT**

41 *Background*

42 The majority of *Plasmodium falciparum* malaria diagnoses in Africa are made using rapid
43 diagnostic tests (RDTs) that detect histidine-rich protein 2. Increasing reports of false-
44 negative RDT results due to parasites with deletions of the *pfhrp2* and/or *pfhrp3* genes
45 (*pfhrp2/3*) raise concern about existing malaria diagnostic strategies. We previously
46 identified *pfhrp2*-negative parasites among asymptomatic children in the Democratic
47 Republic of the Congo (DRC), but their impact on diagnosis of symptomatic malaria is
48 unknown.

49

50 *Methods*

51 We performed a cross-sectional study of false-negative RDTs in symptomatic subjects in
52 2017. Parasites were characterized by microscopy; RDT; *pfhrp2/3* genotyping and species-
53 specific PCR assays; a multiplex bead-based immunoassay; and/or whole-genome
54 sequencing.

55

56 *Results*

57 Among 3,627 symptomatic subjects, we identified 427 (11.8%) RDT-/microscopy+ cases.
58 Parasites from eight (0.2%) samples were initially classified as putative *pfhrp2/3* deletions
59 by PCR, but antigen testing and whole-genome sequencing confirmed the presence of intact
60 genes. Malaria prevalence was high (57%) and non-falciparum co-infection common
61 (15%). HRP2-based RDT performance was satisfactory and superior to microscopy.

62

63 *Conclusions*

64 Symptomatic malaria due to *pfhrp2/3*-deleted *P. falciparum* was not observed in the DRC.

65 Ongoing HRP2-based RDT use is appropriate for the detection of falciparum malaria in the

66 DRC.

67 **BACKGROUND**

68 Emergence of *Plasmodium falciparum* strains that evade detection by rapid
69 diagnostic tests (RDTs) threatens progress toward malaria control and elimination in
70 Africa.[1–3] These parasites have deletions involving the histidine-rich protein 2 and/or 3
71 (*pfhrp2/3*) genes, which encode the proteins detected by widely used RDTs throughout
72 Africa.[4] Increasing reports of these parasites in select locations across Africa raise
73 concern about the future of HRP2-based RDTs in the region.[5–7] Recent events in Eritrea,
74 where a high frequency of false-negative RDTs due to these parasites triggered a change in
75 national malaria diagnostic policy, emphasize the need for surveillance and a coordinated
76 response to *pfhrp2/3*-deleted *P. falciparum*.[8,9]

77 We previously performed the first national survey of *pfhrp2* deletions and reported
78 a 6.4% national prevalence of *pfhrp2*-negative parasites among asymptomatic children in
79 the Democratic Republic of the Congo (DRC).[10] While this cross-sectional, nationally
80 representative household survey enabled spatial analyses and initial population genetic
81 analyses of *pfhrp2*-negative parasites in the DRC, it did not sample subjects with
82 symptomatic malaria. In order to inform decisions about national malaria diagnostic
83 testing policy, we undertook a cross-sectional survey of children and adults presenting to
84 government health facilities in three provinces selected based on the prevalence of *pfhrp2*-
85 negative parasites in our initial study. We hypothesized that *pfhrp2/3*-deleted parasites
86 were responsible for missed clinical cases of falciparum malaria in the DRC.

87 Studies of *pfhrp2/3*-deleted *P. falciparum* are difficult due to the challenges of
88 confirming the absence of these genes using conventional approaches.[11,12] These
89 challenges are compounded by inconsistent laboratory methodologies across studies and


90 inherent limitations of *pfhrp2/3* assays that can suffer from variable performance and
91 cross-reactivity.[13,14] In addition, false-negative RDT results are common throughout
92 Africa and typically caused by factors other than *pfhrp2/3* deletions, including operator
93 error, lot-to-lot RDT variability, low-density infections beneath the RDT's limit of detection,
94 and infection by non-falciparum species.[15,16] In order to overcome these challenges, we
95 performed a comprehensive molecular, serological, and genomic evaluation of
96 symptomatic infections to define the causes of false-negative RDTs in the DRC and inform
97 national diagnostic testing policy.

98

99 **RESULTS**

100 *Study subjects*

101 We enrolled 3,627 subjects with symptoms of malaria during November and December
102 2017, distributed across three provinces: 1,203 in Bas-Uele, 1,248 in Kinshasa, and 1,176 in
103 Sud-Kivu (**Figure 1**). Study sites included 18 health facilities located in 18 distinct health
104 areas, spanning six health zones (three health areas per health zone). Baseline
105 characteristics of and malaria diagnostic testing results from enrolled subjects are
106 displayed in **Table 1** and **Supplementary Table 1**. Age, gender, and the use of long-lasting
107 insecticidal bednets was similar across health zones. Study sites included facilities with
108 high, medium, and low symptomatic malaria prevalence. RDT-positive malaria,
109 microscopy-positive malaria, and self-reported malaria diagnosis within the past six
110 months were highest in Bas-Uele and lowest in Sud-Kivu.



111

112 **Figure 1. Study sites** included health facilities in eighteen health areas (triangles) in six
113 health zones located within three provinces (n = number of facilities per province). Health
114 areas in close proximity have overlapping points.

115

116 **Table 1. Characteristics of enrolled study subjects.**

	Overall	Bas-Uele	Kinshasa	Sud-Kivu
Subjects, n	3627	1203	1248	1176
Health zones, n	6	2	2	2
Health areas, n	18	6	6	6
Age, mean years (SD)	20.7 (18.5)	19.5 (17.9)	20.7 (18.7)	22.0 (18.8)
Age strata, n (%)				
<5 years	1025 (28.7)	370 (31.4)	335 (26.8)	320 (27.9)
5-14 years	579 (16.2)	170 (14.4)	271 (21.7)	138 (12.0)
15-24 years	639 (17.9)	232 (19.7)	181 (14.5)	226 (19.7)
25-34 years	513 (14.4)	170 (14.4)	144 (11.5)	199 (17.4)
35-44 years	344 (9.6)	101 (8.6)	131 (10.5)	112 (9.8)
45-54 years	249 (7.0)	73 (6.2)	108 (8.7)	68 (5.9)
55 years and older	223 (6.2)	62 (5.3)	78 (6.2)	83 (7.2)
Female gender, n (%)	2130 (58.7)	780 (64.8)	646 (51.8)	704 (59.9)
Pregnant, n (% of women)	350 (16.4)	105 (13.5)	26 (4.0)	219 (31.1)
Slept under bednet the night before, n (%)	2238 (79.5)	586 (75.9)	902 (80.9)	750 (80.9)
Diagnosed with malaria in the last six months, n (%)	1556 (43.1)	758 (63.0)	462 (37.6)	336 (28.6)
Microscopy-positive, n (%)	1397 (38.7)	500 (41.7)	533 (43.0)	364 (31.0)
RDT-positive, n (%)	1545 (42.6)	758 (63.0)	380 (30.4)	407 (34.6)
RDT-negative, microscopy-positive, n (%)	426 (11.8)	51 (4.2)	267 (21.5)	108 (9.2)
Parasites/μL by microscopy, geometric mean (geometric mean SD factor)	2877 (6.9)	3739 (6.5)	1789 (7.2)	4001 (6.3)

117

118

119 *False-negative RDTs by microscopy*


120 Among 3,627 subjects tested, 1,545 (42.6%) were RDT-positive and 1,397 (38.7%) were

121 microscopy-positive, with 426 (11.8%) RDT-negative but microscopy-positive ('false-

122 negative RDT'). False-negative RDT results were more likely to occur at low microscopy

123 parasite densities, with geometric means of 959 (geometric standard deviation [SD] factor

124 4.2) and 4,675 (geom. SD factor 6.9) parasites/ μ L for RDT- versus RDT+ samples,
125 respectively (t-test $p < 0.001$, **Figure 2**). We observed higher false-negative RDT prevalence
126 in Kinshasa and Sud-Kivu than Bas-Uele, a pattern similar to RDT-/PCR+ results we
127 observed in our original *pfhrp2* survey in asymptomatic children as part of the 2013-14
128 DRC DHS.[10] When tested by *P. falciparum* lactate dehydrogenase (*pfldh*) PCR, 368 (86%)
129 of the 426 RDT-negative/microscopy-positive samples were PCR-negative, a finding
130 consistent with false-positive microscopy calls in this cohort.



131
132 **Figure 2. Parasite densities by microscopy among HRP2-based RDT-negative (red)**
133 **and RDT-positive (blue) isolates.** False-negative RDT results were more likely to occur at
134 low microscopy parasite densities, with geometric means of 959 (geometric standard
135 deviation [SD] factor 4.2) and 4,675 (geom. SD factor 6.9) parasites/ μ L for RDT-negative
136 versus RDT-positive samples, respectively (t-test $p < 0.001$).

137 *Pfhrp2/3 deletion genotyping by PCR*


138 We performed *pfhrp2/3* genotyping using PCR on a subset of samples, including those
139 collected from all 426 subjects with RDT-/microscopy+ results and from 429
140 RDT+/microscopy+ controls selected at random from the same province (**Supplementary**
141 **Figure 1**). Among the RDT- samples, only 23 had parasite densities sufficient for *pfhrp2/3*
142 deletion genotyping by *pfl dh* qPCR (≥ 40 parasites/ μ L).[13] We further characterized these
143 samples and 74 RDT-positive controls selected from the same facilities (n=97 total) using a
144 series of PCR assays for *pfhrp2* and *pfhrp3*, and a final confirmatory PCR assay for *P.*
145 *falciparum beta-tubulin* (*PfBtubulin*). Eight parasites were PCR-negative for *pfhrp2* or
146 *pfhrp3* in duplicate despite having parasite densities well above the PCR assays' limits of
147 detection and successful amplification of a second single-copy gene, consistent with
148 *pfhrp2/3* gene deletions using conventional PCR genotyping criteria.[4,5,17] PCR
149 genotyping suggested six deletions among symptomatic RDT-/microscopy+ subjects (five
150 *pfhrp2-/3-* and one *pfhrp2-/3+*) and two among RDT+/microscopy+ subjects (one *pfhrp2-*
151 */3+* and one *pfhrp2+/3-*). Parasite densities for these eight putative *pfhrp2/3*-deleted
152 samples ranged from 84 to 102,700 parasites/ μ L by qPCR (median 2,929, interquartile
153 range 1,314 to 4,572).

154

155 *Whole-genome sequencing of candidate pfhrp2/3 deletions*

156 However, whole-genome sequencing (WGS) confirmed that all eight putative *pfhrp2/3-*
157 deleted samples had parasites with intact *pfhrp2* and *pfhrp3* genes (**Figure 3**). All eight
158 samples had >5-fold coverage across >80% of the genome, with median sequencing depth
159 ranging from 66-254 reads/position (**Supplementary Figure 2**). Regions of reduced

160 sequencing depth corresponded to differences in the number of histidine repeats
161 compared to the 3D7 reference sequence and did not introduce frame-shift mutations.
162 Mutations in PCR primer binding sites were not observed.



164 **Figure 3. No *pfhrp2* or *pfhrp3* deletions were identified by whole-genome**
165 **sequencing. WGS of five *pfhrp2*⁻/*pfhrp3*⁻, two *pfhrp2*⁻/*pfhrp3*⁺, and one *pfhrp2*⁺/*pfhrp3*⁻ parasites**
166 **originally identified by PCR confirmed intact genes. Each row represents a distinct sample.**
167
168 *Antigenemia assessment using a bead-based immunoassay*

169 Luminex-based serological assessment further confirmed that all eight *pfhrp2/3*-PCR-
 170 negative samples had detectable HRP2 antigenemia, providing confidence that the intact
 171 genes observed during whole-genome sequencing encoded functional HRP2 and/or *P.*
 172 *falciparum* histidine-rich protein 3 (HRP3) proteins. We assessed HRP2 antigenemia in all
 173 97 samples that had undergone *pfhrp2/3* genotyping by PCR. Comparing RDT-negative
 174 versus RDT-positive samples, positivity and background-subtracted mean fluorescence
 175 intensity (MFI) was similar between groups for all three antigens tested: HRP2,
 176 *Plasmodium* parasite lactate dehydrogenase (pLDH), and *Plasmodium* parasite aldolase
 177 (pAldolase) (**Table 2**). Surprisingly, the majority of RDT- samples tested had high levels of
 178 circulating HRP2 detected by Luminex, suggesting that the negative RDT results were likely
 179 due to operator error or RDT failure (**Figure 4**).

180

181 **Table 2. Luminex bead-based immunoassay results.** Frequencies and log-transformed
 182 mean values were compared using the Fisher’s exact test and t-test, respectively.


183 Abbreviations: RDT, rapid diagnostic test; MFI-background, mean fluorescence intensity

184 minus background; SD, standard deviation.

	Overall	RDT- negative	RDT- positive	p
Tested, n	97	23	74	
HRP2-positive, n (%)	96 (99.0)	22 (95.7)	74 (100.0)	0.24
HRP2, MFI-background geom. mean (SD factor)	10276 (2.9)	11751 (1.7)	6675 (7)	0.31
pLDH-positive, n (%)	72 (74.2)	15 (65.2)	57 (77.0)	0.28
pLDH, MFI-background geom. mean (SD factor)	408 (8.4)	440 (9)	319 (6.5)	0.50
pAldolase-positive, n (%)	92 (94.8)	21 (91.3)	71 (95.9)	0.56
pAldolase, MFI-background geom. mean (SD factor)	1419 (5.5)	1571 (5.4)	1022 (5.9)	0.48

185

186



187

188 **Figure 4. False-negative RDT results occurred in the setting of high HRP2**

189 **antigenemia.** A Luminex bead-based immunoassay for three parasite antigens confirmed

190 circulating HRP2 antigen in the majority of RDT-negative but PCR-positive/microscopy-

191 positive isolates tested (RDT-negative). RDT-positive controls selected from the same

192 facility are included for comparison. Abbreviations: MFI, mean fluorescence intensity; RDT,

193 rapid diagnostic test.

194

195 *Non-falciparum malaria*

196 Non-falciparum malaria is expected to cause HRP2-RDT-negative/microscopy-positive

197 results and was common in our study cohort. Among 1,000 randomly selected samples that

198 underwent species-identification using a series of real-time PCR assays (**Supplementary**

199 **Figure 1**), malaria prevalence was high (57%), and non-falciparum co-infection with *P.*

200 *falciparum* was common (15%, n=150) (**Table 3**). However, only 2.1% (n=11) of

201 symptomatic cases were due to non-falciparum infections alone. *P. ovale* was observed in

202 12.0% (n=68) of symptomatic cases. Among the four (0.8%) symptomatic cases involving

203 *P. vivax*, half involved *P. falciparum* and all were low density (<5 parasites/ μ L by semi-
 204 quantitative 18S rRNA PCR). The majority of symptomatic *P. malariae* infections (86.9%,
 205 n=20/23) occurred as part of mixed infections with *P. falciparum* (**Supplementary Figure**
 206 **3**). We were unable to determine the species in 19 samples that were positive by the pan-
 207 species 18S PCR assay in duplicate; all had negative *P. knowlesi* PCR results.

208

209 **Table 3. Species identification by PCR among subjects with symptomatic malaria.**

210 Results of *Plasmodium* genus and species-specific 18S rRNA real-time PCR assays. Kruskal-

211 Wallis p values are included for province-wise comparisons. Abbreviations: Pf, *P.*

212 *falciparum*; Pm, *P. malariae*; Po, *P. ovale*; Pv, *P. vivax*.

	Overall	Bas-Uele	Kinshasa	Sud-Kivu	p
n	1000	328	353	319	
<i>Plasmodium</i> (any species) PCR-positive, n (%)	568 (56.8)	280 (85.4)	114 (32.3)	174 (54.5)	<0.001
<i>P. falciparum</i> PCR-positive, n (%)	538 (53.8)	268 (81.7)	104 (29.5)	166 (52.0)	<0.001
Species identification by PCR, n (%)					0.001
<i>P. falciparum</i> only	463 (81.5)	210 (75.0)	97 (85.1)	156 (89.7)	
<i>P. malariae</i> only	2 (0.4)	2 (0.7)	0 (0.0)	0 (0.0)	
<i>P. ovale</i> only	6 (1.1)	1 (0.4)	4 (3.5)	1 (0.6)	
<i>P. vivax</i> only	2 (0.4)	1 (0.4)	0 (0.0)	1 (0.6)	
Mixed Pf and Pm	16 (2.8)	12 (4.3)	1 (0.9)	3 (1.7)	
Mixed Pf and Po	53 (9.3)	42 (15.0)	5 (4.4)	6 (3.4)	
Mixed Pf and Pv	2 (0.4)	1 (0.4)	0 (0.0)	1 (0.6)	
Mixed Pm and Po	1 (0.2)	1 (0.4)	0 (0.0)	0 (0.0)	
Mixed Pf, Pm, Po	4 (0.7)	3 (1.1)	1 (0.9)	0 (0.0)	
<i>Plasmodium</i> positive, species undetermined	19 (3.3)	7 (2.5)	6 (5.3)	6 (3.4)	

213

214

215 RDT performance

216 Assessment of RDT performance versus PCR suggested that false-negative RDT results in
217 our cohort were commonly caused by RDT failure or operator error rather than parasite
218 factors. Among the random subset of 1,000 samples that underwent 18S rRNA testing for
219 all species, 134 (13.4%) of 538 *P. falciparum* 18S real-time PCR-positive samples were
220 RDT-negative. RDT performance varied by province, with a larger proportion of RDT-
221 /PCR+ results in provinces with higher *P. falciparum* prevalence by 18S rRNA PCR: Bas-
222 Uele (19%), followed by Sud-Kivu (17%), and finally Kinshasa (5%) (**Supplementary**
223 **Table 2**). Only a small proportion of samples (3.6%, n=36) were RDT+/PCR-, a finding not
224 unexpected and suggestive of persistent PfHRP2 antigenemia after recent clearance of
225 parasitemia.[18] When compared with PCR, RDTs were 75% sensitive and 92% specific,
226 with good agreement (kappa = 0.66). Microscopy was 53% sensitive and 81% specific, with
227 fair agreement with PCR (kappa = 0.33). Parasite densities as determined by microscopy
228 and *pfdh* quantitative PCR (qPCR) had moderate correlation (Spearman correlation
229 coefficient = 0.63, p <0.001, **Supplementary Figure 4**).

230

231 DISCUSSION

232 We did not observe symptomatic malaria due to *pfhrp2*- or *pfhrp3*-deleted *P.*
233 *falciparum* in this large, cross-sectional survey across three geographically disparate DRC
234 provinces. The majority of RDT-negative/microscopy-positive results occurred in the
235 setting of low or absent parasitemia. This finding implicates low parasite densities beneath
236 the RDT's limit of detection and false-positive microscopy results as the primary causes of
237 RDT-microscopy discordance in the present study. Further assessment of RDT

238 performance using microscopy, genus- and species-specific real-time PCR assays, and
239 Luminex-based antigenemia assessment confirmed that RDT failure and/or user error also
240 caused false-negative RDTs in the present study. However, the overall performance of
241 HRP2-based RDTs was superior to microscopy and in good agreement with PCR.

242 These findings support continued use of HRP2-based RDTs in the DRC. They also
243 contrast with the results of our prior study of asymptomatic children enrolled in the 2013-
244 14 Demographic and Health Survey (DHS). There are several possible explanations for
245 these differences. The present study enrolled symptomatic subjects in order to directly
246 inform policy decisions about malaria case management. This study design could have
247 inhibited our ability to identify *pfhrp2/3*-deleted parasites. We and others have proposed
248 the hypothesis that parasites with deletions of the *pfhrp2* and/or *pfhrp3* genes and their
249 flanking regions may be less fit,[6,10,19] and therefore less likely to cause symptomatic
250 disease. Direct assessment of this hypothesis has not yet been performed *in vivo* or *in vitro*,
251 to our knowledge. However, genetic cross experiments of the 3D7 (wild-type), DD2
252 (*pfhrp2*-deleted), and HB3 (*pfhrp3*-deleted) lab strains did not provide clear evidence of a
253 fitness cost associated with deletion of either gene.[20,21] In addition, reports from Eritrea
254 confirm that *pfhrp2/3*-deleted parasites can cause symptomatic and sometimes severe
255 disease.[8]

256 Exhaustive analysis of putative *pfhrp2/3*-deleted parasites was needed to discern
257 the status of both genes. The use of rigorous parasite density thresholds well above the
258 downstream *pfhrp2/3* PCR assays' limit of detection,[13] confirmation of successful
259 amplification of multiple single-copy genes, and adherence to commonly accepted
260 criteria[5] reduced the risk of inappropriate *pfhrp2/3* deletion calls. Only eight of 426

261 (1.8%) RDT-negative/microscopy-positive samples were identified as putative *pfhrp2/3*
262 deletions during initial testing. However, we subsequently confirmed HRP2 antigenemia
263 and intact *pfhrp2* and *pfhrp3* genes in all eight samples using highly sensitive antigen
264 detection methods and WGS, respectively, confirming that these putative *pfhrp2/3*-deleted
265 parasites were misclassified during initial testing.

266 These findings emphasize the challenges of confirming *pfhrp2/3* gene deletions and
267 support the argument that a portion of *pfhrp2/3* deletion calls in our original study of
268 asymptomatic children in the DRC were artifactual.[10,11] Even complex laboratory
269 workflows conducted in accordance with commonly used deletion classification criteria are
270 not always sufficient to eliminate the risk of misclassification of *pfhrp2/3* deletions. The use
271 of advanced serological and next-generation sequencing methods improved the quality of
272 our *pfhrp2/3* deletion assessment, allowed for a more robust evaluation of RDT
273 performance, and enabled visualization of the genetic structure of the *pfhrp2* and *pfhrp3*
274 genes and their flanking regions. While these methodologies are not widely available in
275 resource-limited settings, they are now accessible through a network of laboratories that
276 collaborate with the World Health Organization to support *pfhrp2/3* deletion
277 surveillance[22] and in select locales in sub-Saharan Africa with advanced laboratory
278 capacity.

279 Symptomatic malaria due non-falciparum species was common but usually occurred
280 as part of mixed infections with *P. falciparum*. Although non-falciparum species are not
281 detected by widely deployed HRP2-based RDTs, co-infection with *P. falciparum* is expected
282 to trigger a positive RDT result and prompt treatment with artemisinin-combination
283 therapy according to current DRC guidelines. Therefore, complications due to untreated

284 symptomatic, non-falciparum malaria are likely uncommon, although the risk of relapse by
285 *P. vivax* or *P. ovale* without proper diagnosis and terminal prophylaxis remains. Our
286 findings are generally in-line with prior reports of non-falciparum infection among
287 asymptomatic subjects in the DRC.[23–25]

288 Strengths of this study include its geographically diverse sampling locations, robust
289 pipeline of conventional and advanced laboratory methodologies, and relevance to malaria
290 case management. Indeed, these findings directly informed the DRC national malaria
291 control program’s decision to continue the use of HRP2-based RDTs, despite evidence of
292 *pfhrp2*-negative parasites from our initial study of asymptomatic subjects. Our experience
293 in the DRC confirms the importance of basing policy decisions on careful studies of the
294 target population - individuals presenting to health facilities with symptomatic malaria -
295 rather than convenience sampling.

296 Limitations include our inability to discriminate *pfhrp2/3*-deleted from *pfhrp2/3*-
297 intact strains in individuals infected by multiple *P. falciparum* strains. Neither the
298 conventional methods nor the advanced Luminex-based HRP2 antigenemia assessment
299 and WGS methods employed here are well-suited to identify gene deletions in mixed
300 infections. Recently developed multiplexed qPCR methods[26] and amplicon-based deep
301 sequencing approaches[27] have potential to elucidate *pfhrp2/3*-deleted minor variants in
302 future large-scale surveys. Additionally, we restricted our *pfhrp2/3* deletion analysis to
303 samples with ≥ 40 parasites/ μL . This requirement was necessary to reduce the risk of
304 misclassification due to DNA concentrations beneath the *pfhrp2/3* PCR assays’ limits of
305 detection,[13] but it prevents us from commenting on the prevalence of deletions in lower
306 density infections. Finally, this study was restricted to three provinces. These provinces

307 spanned a range of malaria prevalence, but they do not capture the full diversity of the
308 DRC, which is Africa's second largest country by land mass and neighbors nine other
309 countries.

310 In conclusion, ongoing HRP2-based RDT use is appropriate in the DRC. False-
311 negative RDT results due to *pfhrp2/3* deletions were not observed among symptomatic
312 subjects. Non-falciparum infection was an uncommon cause of false-negative results in the
313 DRC, and RDT performance was superior to microscopy. Careful laboratory workflows are
314 required during *pfhrp2/3* gene deletion analyses. Advanced serological and next-
315 generation sequencing approaches can be used to improve the rigor and reproducibility of
316 *pfhrp2/3* deletion surveillance efforts and to inform malaria diagnostic testing policy.

317

318 **METHODS**

319 *Study population*

320 We conducted a cross-sectional study of subjects presenting to hospitals and health centers
321 across three provinces (Kinshasa, Bas-Uele, and Sud-Kivu) with symptoms of malaria.
322 These provinces were selected based on results from our prior survey of asymptomatic
323 children in the 2013-14 DHS and included both high- (Kinshasa, Sud-Kivu) and low-
324 prevalence (Bas-Uele) of *pfhrp2*-negative parasites.[10] Two health zones were selected
325 from each province, including one urban and one rural zone per province. Within each
326 health zone, one general reference hospital and two health centers were selected as study
327 sites, yielding six study sites per province and 18 study sites in total. Subjects of all ages
328 were eligible for enrollment.

329

330 *Study procedures*

331 Informed consent/assent was obtained from all study subjects prior to enrollment. All
332 subjects received malaria RDT testing and treatment according to DRC national guidelines.
333 Subjects underwent a study questionnaire and finger- or heel-prick whole blood collection
334 for diagnostic testing by RDT and microscopy and DBS collection. RDT testing was
335 performed using the WHO-prequalified, HRP2-based SD BIOLINE Malaria Ag P.f. (05FK50,
336 Alere, Waltham, MA) according to manufacturer instructions. Thick-smear microscopy
337 slides were read in the field, and thin smears fixed and transported to the National AIDS
338 Control (PNLS) reference laboratory for confirmation and determination of parasite
339 density. All thin smears were read by two microscopists, with discrepancies resolved by a
340 third reader. DBS (Whatmann 903 Protein Saver cards, GE Healthcare Life Sciences,
341 Marlborough, MA) were allowed to air dry at ambient temperature in the field, and stored
342 in individual ziplock bags with desiccant at -20°C prior to and after shipment to the
343 University of North Carolina at Chapel Hill for further testing. This study was approved by
344 the Ethical Committee of the Kinshasa School of Public Health and the UNC Institutional
345 Review Board.

346

347 *Pfhrp2/3 genotyping by PCR*

348 DNA was extracted from DBS samples using Chelex and saponin.[28] All microscopy-
349 positive, RDT-negative samples, in addition to an equal number of microscopy-positive,
350 RDT-positive controls from each province were subjected to qPCR testing targeting the
351 single-copy *P. pfldh* gene.[29] *Pfhrp2* and *pfhrp3* PCR genotyping was performed as
352 previously described,[13] using conventional single-step *pfhrp2/3* PCR assays and a

353 qualitative real-time PCR assay targeting the single-copy *PfBtubulin* gene (**Supplementary**
354 **File**).[30–33] Only samples with ≥ 40 parasites/ μL by qPCR (≥ 10 -fold higher concentration
355 than the *pfhrp2* and *pfhrp3* assays' limits of detection) were subjected to *pfhrp2* and *pfhrp3*
356 PCR to reduce the risk of misclassification of deletions.[13] Microscopy-positive, RDT-
357 positive controls with ≥ 40 parasites/ μL by qPCR were randomly selected from the same
358 facility for *pfhrp2/3* genotyping. Samples were called *pfhrp2/3*-negative if they had ≥ 40
359 parasites/ μL by *pfdh* qPCR, their *pfhrp2* and/or *pfhrp3* PCR assays were negative in
360 duplicate, and they had successful amplification of *PfBtubulin* during a final confirmatory
361 assay.

362

363 *Whole-genome sequencing*

364 All *pfhrp2/3*-negative samples identified during initial testing were further assessed using
365 whole-genome sequencing. DNA from these samples was enriched for *P. falciparum* prior
366 to library prep using selective whole-genome amplification (sWGA) as previously
367 described.[34] In brief, two sWGA reactions were performed in parallel, one using a custom
368 primer set designed in our lab (JP9) and another using a primer set designed by Oyola *et al*
369 (Probe_10).[35] sWGA products were pooled in equal volumes and acoustically sheared
370 using a Covaris E220 instrument prior to library preparation using the Kapa HyperPrep kit
371 (Roche Sequencing, Pleasanton, CA). Indexed libraries were pooled and sequenced at the
372 UNC High Throughput Sequencing Facility using the HiSeq 2500 platform (Illumina, San
373 Diego, CA) with 150bp, paired-end chemistry. Sequence reads were deposited into the
374 Sequence Read Archive (accession numbers: pending).

375

376 *Evaluation for pfhrp2/3 deletions using whole-genome sequencing*

377 Adapter sequences were trimmed from raw, paired sequence reads using *trimmomatic* and
378 aligned to the *P. falciparum* 3D7 reference genome (PlasmoDB version 13.0) using *bwa*
379 *mem* with default parameters.[36,37] Duplicates were marked and mate-pair information
380 corrected using Picard Tool's *MarkDuplicates* and *FixMateInformation* functions,
381 respectively.[38] Candidate indels were identified and realigned using GATK's
382 *RealignerTargetCreator* and *IndelAligner* functions, respectively.[39] Genome coverage was
383 calculated using *bedtool's genomecov* function and visualized using *ggplot2* in R (R Core
384 Team, Vienna, Austria).[40,41] *Pfhrp2/3* deletions were called by visualization of aligned
385 reads using the Integrative Genomics Viewer (Broad Institute, Cambridge, MA) and
386 assessment of sequencing depth across the *pfhrp2/3* genes and their flanking regions.[42]

387

388 *Antigenemia assessment by Luminex*

389 All DBS samples subjected to *pfhrp2/3* genotyping by PCR were also assayed for the
390 following *Plasmodium* antigens: *Plasmodium* genus-specific aldolase (pAldolase) and
391 lactate dehydrogenase (pLDH), as well as *P. falciparum* HRP2 by a bead-based multiplex
392 assay as previously described.[43] Samples were assayed at 1:20 whole-blood
393 concentration after elution from filter paper. Thresholds for antigen positivity for the three
394 targets were determined by assaying 92 blood samples from US resident blood donors
395 without history of international travel and determining mean and standard deviation of
396 assay signal from this sample set. The mean plus three standard deviations of this sample
397 set was used as the antigen positivity threshold.

398

399 *Non-falciparum assays*

400 We used R to randomly select 1,000 samples for PCR-based species identification. DNA
401 from these samples was first subjected to a pan-*Plasmodium* real-time PCR assay targeting
402 the 18S rRNA gene in duplicate.[44] Any sample with at least one positive pan-*Plasmodium*
403 replicate was subjected to a series of four 18S rRNA real-time PCR assays specific to *P.*
404 *falciparum*, *Plasmodium malariae*, *Plasmodium ovale*, and *P. vivax* in duplicate.[45–47]
405 Species calls were only made if at least two total replicates were positive. Samples with
406 only a single positive pan-*Plasmodium* replicate but negative species-specific assays were
407 called negative. Samples in which both pan-*Plasmodium* replicates were positive but
408 species-specific assays negative were subjected to a PCR assay specific to the *Plasmodium*
409 *knowlesi* Pkr140 gene.[48] PCR primers and reaction conditions are described in the
410 **Supplementary File.**

411

412 *Data analysis*

413 We made comparisons using the Kruskal-Wallis Rank Sum or Fisher's exact test for
414 categorical variables and the t-test for normally distributed continuous variables. Statistical
415 analyses were performed using R software.

416

417 **FOOTNOTES**

418 *Acknowledgements*

419 The authors thank Steven Meshnick for his key role in conceptualizing this study and
420 interpretation of results, and Nicholas Brazeau for assistance with bioinformatic pipelines
421 and whole-genome sequencing summary statistic visualization. They also thank the study

422 supervisors, staff, and participants. The following reagents were obtained through BEI
423 Resources, NIAID, NIH: Genomic DNA from *P. falciparum* strain 3D7, MRA-102G,
424 contributed by Daniel J. Carucci; *P. falciparum* strain HB3, MRA-155G, contributed by
425 Thomas E. Wellems; *P. falciparum* strain Dd2, MRA-150G, contributed by David Walliker;
426 and *P. knowlesi* strain H, MRA-456G, contributed by Alan W. Thomas; in addition to
427 diagnostic plasmid containing the small subunit ribosomal RNA gene (18S) from
428 *Plasmodium vivax*, MRA-178, *Plasmodium ovale*, MRA-180, and *Plasmodium malariae*, MRA-
429 179, contributed by Peter A. Zimmerman.

430

431 *Conflict of interest*

432 JBP reports grant support from the World Health Organization related to the scope of the
433 present study and non-financial support from Abbott Laboratories, outside the scope of the
434 present study. All other authors declare no conflicts of interest.

435

436 *Financial support*

437 This work was supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. It
438 was also partially supported by awards from the National Institutes of Allergy and
439 Infectious Diseases [R01AI132547 to JBP and JJJ] and the Doris Duke Charitable
440 Foundation to JBP.

441

442 *Presentations*

443 Preliminary findings were presented at the American Society for Tropical Medicine and
444 Hygiene in New Orleans, Louisiana, USA, on October 30, 2018, and at the Journées

445 Scientifiques de Lutte contre le Paludisme 2019 conference in Kinshasa, Democratic
446 Republic of Congo on April 30, 2019.

447

448 *Corresponding author*

449 Jonathan B. Parr, MD, MPH, Division of Infectious Diseases, University of North Carolina,
450 130 Mason Farm Rd., Chapel Hill, NC 27599; phone 1-919-445-1132; email

451 jonathan_parr@med.unc.edu.

452

453 *Changes in affiliation*

454 N/A

455

456 **REFERENCES**

- 457 1. World Health Organization. False-negative RDT results and implications of new
458 reports of *P. falciparum* histidine-rich protein 2/3 gene deletions. Geneva: WHO; 2016.
- 459 2. Verma AK, Bharti PK, Das A. HRP-2 deletion: a hole in the ship of malaria elimination.
460 *Lancet Infect Dis.* **2018**; 18(8):826–827.
- 461 3. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria
462 Diagnosis, but with Caveats. *Trends Parasitol.* **2020**; 36(2):112–126.
- 463 4. Cheng Q, Gatton ML, Barnwell J, et al. *Plasmodium falciparum* parasites lacking
464 histidine-rich protein 2 and 3: a review and recommendations for accurate reporting.
465 *Malar J.* **2014**; 13:283.
- 466 5. Thomson R, Parr JB, Cheng Q, Chenet S, Perkinse M, Cunninghame J. Prevalence of
467 *Plasmodium falciparum* lacking histidine-rich proteins 2 and 3: a systematic review.
468 **2020**; 98(8):558-568.
- 469 6. Watson OJ, Slater HC, Verity R, et al. Modelling the drivers of the spread of *Plasmodium*
470 *falciparum* hrp2 gene deletions in sub-Saharan Africa. *Elife.* **2017**; 6:e25008.
- 471 7. Gatton ML, Dunn J, Chaudhry A, Ciketic S, Cunningham J, Cheng Q. Implications of
472 Parasites Lacking *Plasmodium falciparum* Histidine-Rich Protein 2 on Malaria

- 473 Morbidity and Control When Rapid Diagnostic Tests Are Used for Diagnosis. *J Infect*
474 *Dis.* **2017**; 215(7):1156–1166.
- 475 8. Berhane A, Anderson K, Mihreteab S, et al. Major Threat to Malaria Control Programs
476 by *Plasmodium falciparum* Lacking Histidine-Rich Protein 2, Eritrea. *Emerg Infect Dis.*
477 **2018**; 24(3):462–470.
- 478 9. Menegon M, L’Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C.
479 Identification of *Plasmodium falciparum* isolates lacking histidine-rich protein 2 and 3
480 in Eritrea. *Infect Genet Evol.* **2017**; 55:131–134.
- 481 10. Parr JB, Verity R, Doctor SM, et al. Pfhrrp2-Deleted *Plasmodium falciparum* Parasites in
482 the Democratic Republic of the Congo: A National Cross-sectional Survey. *J Infect Dis.*
483 **2017**; 216(1):36–44.
- 484 11. Woodrow CJ, Fanello C. Pfhrrp2 Deletions in the Democratic Republic of Congo:
485 Evidence of Absence, or Absence of Evidence? *J. Infect. Dis.* **2017**; 216(4):504–506.
- 486 12. Parr JB, Meshnick SR. Response to Woodrow and Fanello. *J. Infect. Dis.* **2017**; 216(4):
487 503–504.
- 488 13. Parr JB, Anderson O, Juliano JJ, Meshnick SR. Streamlined, PCR-based testing for
489 pfhrrp2- and pfhrrp3-negative *Plasmodium falciparum*. *Malar J.* **2018**; 17:137.
- 490 14. Jones S, Subramaniam G, Plucinski MM, et al. One-step PCR: A novel protocol for
491 determination of pfhrrp2 deletion status in *Plasmodium falciparum*. *PLoS One.* **2020**;
492 15(7):e0236369.
- 493 15. Watson OJ, Sumner KM, Janko M, et al. False-negative malaria rapid diagnostic test
494 results and their impact on community-based malaria surveys in sub-Saharan Africa.
495 *BMJ Glob Health.* **2019**; 4(4):e001582.
- 496 16. Wu L, Hoogen LL van den, Slater H, et al. Comparison of diagnostics for the detection of
497 asymptomatic *Plasmodium falciparum* infections to inform control and elimination
498 strategies. *Nature.* **2015**; 528(7580):S86–93.
- 499 17. World Health Organization. Protocol for estimating the prevalence of pfhrrp2/pfhrrp3
500 gene deletions among symptomatic falciparum patients with false-negative RDT
501 results. Geneva: WHO, 2018.
- 502 18. Markwalter CF, Gibson LE, Mudenda L, et al. Characterization of *Plasmodium* Lactate
503 Dehydrogenase and Histidine-Rich Protein 2 Clearance Patterns via Rapid On-Bead
504 Detection from a Single Dried Blood Spot. *Am J Trop Med Hyg.* **2018**; 98(5):1389–
505 1396.
- 506 19. Pati P, Dhangadamajhi G, Bal M, Ranjit M. High proportions of pfhrrp2 gene deletion
507 and performance of HRP2-based rapid diagnostic test in *Plasmodium falciparum* field

- 508 isolates of Odisha. *Malar J.* **2018**; 17(1):394.
- 509 20. Walker-Jonah A, Dolan SA, Gwadz RW, Panton LJ, Wellems TE. An RFLP map of the
510 *Plasmodium falciparum* genome, recombination rates and favored linkage groups in a
511 genetic cross. *Mol Biochem Parasitol.* **1992**; 51(2):313–320.
- 512 21. Sepúlveda N, Phelan J, Diez-Benavente E, et al. Global analysis of *Plasmodium*
513 *falciparum* histidine-rich protein-2 (pfrhp2) and pfrhp3 gene deletions using whole-
514 genome sequencing data and meta-analysis. *Infect Genet Evol.* **2018**; 62:211–219.
- 515 22. World Health Organization. Response plan to pfrhp2 gene deletions. Geneva: WHO,
516 2019. Available from:
517 [https://apps.who.int/iris/bitstream/handle/10665/325528/WHO-CDS-GMP-](https://apps.who.int/iris/bitstream/handle/10665/325528/WHO-CDS-GMP-2019.02-eng.pdf?ua=1)
518 [2019.02-eng.pdf?ua=1](https://apps.who.int/iris/bitstream/handle/10665/325528/WHO-CDS-GMP-2019.02-eng.pdf?ua=1)
- 519 23. Taylor SM, Messina JP, Hand CC, et al. Molecular Malaria Epidemiology: Mapping and
520 Burden Estimates for the Democratic Republic of the Congo, 2007. *PLoS One.* **2011**;
521 6(1):e16420.
- 522 24. Brazeau NF, Mitchell CL, Morgan AP, et al. The Epidemiology of *Plasmodium vivax*
523 Among Adults in the Democratic Republic of the Congo: A Nationally-Representative,
524 Cross-Sectional Survey. *Epidemiology.* medRxiv; 2020. Available from:
525 <https://www.medrxiv.org/content/10.1101/2020.02.17.20024190v1.abstract>
- 526 25. Mitchell CL, Brazeau NF, Keeler C, et al. Under the Radar: Epidemiology of *Plasmodium*
527 *ovale* in the Democratic Republic of the Congo. *J Infect Dis.* **2020** [epub ahead of print
528 on 7 Aug 2020. Available from: <http://dx.doi.org/10.1093/infdis/jiaa478>]
- 529 26. Grignard L, Nolder D, Sepúlveda N, et al. A Novel Multiplex qPCR Assay for Detection of
530 *Plasmodium falciparum* with Histidine-rich Protein 2 and 3 (pfrhp2 and pfrhp3)
531 Deletions in Polyclonal Infections. *EBioMedicine.* **2020**; 55:102757.
- 532 27. Verity R, Aydemir O, Brazeau NF, et al. The impact of antimalarial resistance on the
533 genetic structure of *Plasmodium falciparum* in the DRC. *Nat Commun.* **2020**;
534 11(1):2107.
- 535 28. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil
536 resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase:
537 polymerase chain reaction methods for surveillance in Africa. *Am J Trop Med Hyg.*
538 **1995**; 52(6):565–568.
- 539 29. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to Antimalarials in
540 Southeast Asia and Genetic Polymorphisms in pfmdr1. *Antimicrob Agents Chem.*
541 **2003**; 47(8):2418–2423.
- 542 30. Baker J, McCarthy J, Gatton M, et al. Genetic diversity of *Plasmodium falciparum*
543 histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based

- 544 rapid diagnostic tests. *J Infect Dis.* **2005**; 192(5):870–877.
- 545 31. Koita OA, Doumbo OK, Ouattara A, et al. False-negative rapid diagnostic tests for
546 malaria and deletion of the histidine-rich repeat region of the *hrp2* gene. *Am J Trop*
547 *Med Hyg.* **2012**; 86(2):194–198.
- 548 32. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in *Plasmodium*
549 *falciparum* and increased *pfmdr1* gene copy number. *Lancet.* **2004**; 364(9432):438–
550 447.
- 551 33. Afonina I, Ankoudinova I, Mills A, Lokhov S, Huynh P, Mahoney W. Primers with 5'
552 flaps improve real-time PCR. *Biotechniques.* **2007**; 43(6):770, 772, 774.
- 553 34. Morgan AP, Brazeau NF, Ngasala B, et al. *Falciparum* malaria from coastal Tanzania
554 and Zanzibar remains highly connected despite effective control efforts on the
555 archipelago. *Malar J.* **2019**; 19(1):47.
- 556 35. Oyola SO, Ariani CV, Hamilton WL, et al. Whole genome sequencing of *Plasmodium*
557 *falciparum* from dried blood spots using selective whole genome amplification. *Malar*
558 *J.* **2016**; 15(1):597.
- 559 36. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
560 data. *Bioinformatics.* **2014**; 30(15):2114–2120.
- 561 37. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
562 arXiv; 2013 Mar p. 3.
- 563 38. Broad Institute. Picard tools. Broad Institute, GitHub repository available at
564 <https://broadinstitute.github.io/picard/>.
- 565 39. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce
566 framework for analyzing next-generation DNA sequencing data. *Genome Res.* **2010**;
567 20(9):1297–1303.
- 568 40. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic
569 features. *Bioinformatics.* **2010**; 26(6):841–842.
- 570 41. Wickham H. *ggplot2*. 1st ed. New York: Springer-Verlag; 2009.
- 571 42. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. *Nat*
572 *Biotechnol.* **2011**; 29(1):24–26.
- 573 43. Plucinski MM, Herman C, Jones S, et al. Screening for *Pfhrp2/3*-Deleted *Plasmodium*
574 *falciparum*, Non-*falciparum*, and Low-Density Malaria Infections by a Multiplex
575 Antigen Assay. *J Infect Dis.* **2019**; 219(3):437–447.
- 576 44. Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. Multiplex qPCR for
577 detection and absolute quantification of malaria. *PLoS One.* **2013**; 8(8):e71539.

- 578 45. Srisutham S, Saralamba N, Malleret B, Rénia L, Dondorp AM, Imwong M. Four human
579 Plasmodium species quantification using droplet digital PCR. PLoS One. **2017**;
580 12(4):e0175771.
- 581 46. Veron V, Simon S, Carme B. Multiplex real-time PCR detection of *P. falciparum*, *P. vivax*
582 and *P. malariae* in human blood samples. Exp Parasitol. **2009**; 121(4):346–351.
- 583 47. Perandin F, Manca N, Calderaro A, et al. Development of a real-time PCR assay for
584 detection of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale for
585 routine clinical diagnosis. J Clin Microbiol. **2004**; 42(3):1214–1219.
- 586 48. Lucchi NW, Poorak M, Oberstaller J, et al. A new single-step PCR assay for the detection
587 of the zoonotic malaria parasite Plasmodium knowlesi. PLoS One. **2012**; 7(2):e31848.

588 **SUPPLEMENTARY MATERIAL**


589

590 **Supplementary Table 1. Characteristics of study subjects by health zone.**


Province Health zone	Overall	Bas-Uele		Kinshasa		Sud-Kivu	
		Buta	Ganga	Limete	Nsele	Idjwi	Kadutu
n	3627	598	605	629	619	587	589
Age, mean years (SD)	20.7 (18.5)	18.4 (17.5)	20.6 (18.2)	20.8 (18.8)	20.7 (18.6)	21.2 (18.5)	22.9 (19.2)
Age strata, n (%)							
<5 years	1025 (28.7)	177 (30.7)	193 (32.1)	188 (29.9)	147 (23.7)	179 (30.5)	141 (25.2)
5-14 years	579 (16.2)	107 (18.5)	63 (10.5)	115 (18.3)	156 (25.2)	51 (8.7)	87 (15.6)
15-24 years	639 (17.9)	116 (20.1)	116 (19.3)	95 (15.1)	86 (13.9)	133 (22.7)	93 (16.6)
25-34 years	513 (14.4)	79 (13.7)	91 (15.1)	64 (10.2)	80 (12.9)	107 (18.2)	92 (16.5)
35-44 years	344 (9.6)	34 (5.9)	67 (11.1)	64 (10.2)	67 (10.8)	50 (8.5)	62 (11.1)
45-54 years	249 (7.0)	37 (6.4)	36 (6.0)	66 (10.5)	42 (6.8)	31 (5.3)	37 (6.6)
55 years and older	223 (6.2)	27 (4.7)	35 (5.8)	37 (5.9)	41 (6.6)	36 (6.1)	47 (8.4)
Female gender, n (%)	2130 (58.7)	403 (67.4)	377 (62.3)	302 (48.0)	344 (55.6)	342 (58.3)	362 (61.5)
Pregnant, n (%)	350 (16.4)	81 (20.1)	24 (6.4)	4 (1.3)	22 (6.4)	119 (34.8)	100 (27.6)
Slept under bednet the night before, n (%)	2238 (79.5)	396 (93.8)	190 (54.3)	480 (85.6)	422 (76.2)	355 (85.7)	395 (77.0)
Diagnosed with malaria in the last six months, n (%)	1556 (43.1)	390 (65.2)	368 (60.8)	173 (28.3)	289 (46.8)	196 (33.4)	140 (23.8)
Microscopy-positive, n (%)	1397 (38.7)	189 (31.7)	311 (51.6)	246 (39.5)	287 (46.6)	298 (50.8)	66 (11.2)
RDT-positive, n (%)	1545 (42.6)	334 (55.9)	424 (70.1)	99 (15.7)	281 (45.4)	342 (58.3)	65 (11.0)
RDT-negative, microscopy-positive, n (%)	426 (11.8)	14 (2.3)	37 (6.1)	178 (28.5)	89 (14.4)	69 (11.8)	39 (6.6)

591 **Supplementary Table 2. Comparison of malaria diagnostic test results: HRP2-based**
 592 **RDT, *P. falciparum* 18S rRNA real-time PCR, and microscopy (micro) comparisons, counts**
 593 **(percent). A) RDT versus PCR. B) RDT versus microscopy. C) Microscopy versus PCR. D)**
 594 **RDT and PCR profiles by province.**
 595

A.		PCR+	PCR-		
	RDT+	404 (40)	36 (4)		
	RDT-	134 (13)	426 (43)		
B.		Micro+	Micro-		
	RDT+	267 (27)	173 (17)		
	RDT-	108 (11)	452 (45)		
C.		PCR+	PCR-		
	Micro+	287 (29)	88 (9)		
	Micro-	251 (25)	374 (37)		
D.		RDT-/PCR-	RDT-/PCR+	RDT+/PCR+	RDT+/PCR-
Province	Kinshasa	234 (66)	17 (5)	87 (25)	15 (4)
	Sud-Kivu	142 (45)	54 (17)	112 (35)	11 (3)
	Bas-Uele	50 (15)	63 (19)	205 (62)	10 (3)




Supplementary Figure 1. Sample selection for assessment of *pfhrp2/3* deletions and diagnostic performance. Abbreviations: Pf, *P. falciparum*; Pm, *P. malariae*; Po, *P. ovale*; Pv, *P. vivax*; Pk, *P. knowlesi*.



Summary of Coverage Depth by Sample


smpl	n	min	q25	median	mean	q75	max
SANHRP_01_CTATAC_S1_L004	23332839	0	74	138	214.48137	254	150751
SANHRP_02_CTCAGA_S2_L004	23332839	0	134	237	349.39586	422	237333
SANHRP_03_GCGCTA_S3_L004	23332839	0	76	133	190.67555	232	129011
SANHRP_04_TAAATCG_S4_L004	23332839	0	50	94	148.57108	175	100947
SANHRP_05_TACAGC_S5_L004	23332839	0	36	66	97.06442	118	71313
SANHRP_06_TATAAT_S6_L004	23332839	0	143	254	367.86268	445	268162
SANHRP_07_TCGAAG_S7_L004	23332839	0	77	169	330.98488	374	219252
SANHRP_08_TCGGCA_S8_L004	23332839	0	122	203	263.40878	330	202749

Supplementary Figure 2. Genomic coverage statistics by sample.



Supplementary Figure 3. Malaria prevalence was high (57% overall) and non-falciparum co-infection common (15% overall) among symptomatic subjects.

Plasmodium PCR prevalence and species-specific real-time PCR results for *P. falciparum*, *P. ovale*, *P. malariae*, and *P. vivax* among 1,000 samples tested, with counts reported by province. Province-level prevalence of pan-*Plasmodium* PCR-positivity is displayed in white font.



Supplementary Figure 4. Parasite densities determined by *pfladh* qPCR and microscopy were similar, with moderate correlation (Spearman correlation coefficient = 0.63, $p < 0.001$).

Supplementary File. PCR primers, probes, and reaction conditions.